Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yea tomorrow after close plus update. Lets see!
Best of luck with that
Ok buddy
ok. again, best of luck.
selling now makes ZERO sense. With what is coming soon. unless you need money to pay bills.
good. they will have to cover. best of luck to you!
Lol. Nice try. Stick around for friday and the weekend
relax Cherry. I think you will be very happy soon
they don't just put out pr's for fun. these guys do things by the book. We are going to be rewarded soon.
I hear ya. No reason for us to be below $2-$2.50 right now imo. All good!
We don't Need it but it is coming
IMO $1.80 is low by Fri. We were at $3.23 with no news. We shall see very soon. Take care.
friday is the day for that PLUS News update
you are getting it. you understand. bravo. plus more than you think.
not inside info. just do some digging. some things are happening that could not happen unless other things happened!
LOL. you could not be more wrong here. oh man
From my guy at Merrill:
Shareholders should get very nice update this Fri. Best co in the sector by far.
yessir. no doubt.
Looking for Cannabis ETF link. anyone have link to the fund - the co?
gotcha. anyone have link to the etf site?
link please? that is big if true
This is huge. Huge huge . Thx
Lol. Nope
I have 1.8 million shares. Fact. No reason to sell anything below $10,15$,20$
I'm long. Never sold a share. 1.8 million. No reason to sell until $15-20$
I'm on vacation. Just saw the news!
OWC Pharmaceutical Research Corp OWCP:OTCQB
The Data Surrounding the Legal Cannabis Markets
PR Newswire
9:00 AM ET
FinancialBuzz.com News Commentary
In a recent report by Arcview Market Research, the legal cannabis market is arguably the fastest growing industry in the world. The data reported shows, that regulated cannabis sales in North America totaled $6.9 billion in 2016, a 30 percent increase from 2015. Sales are projected to increase to $21.6 billion by the year 2021, representing a 26 percent compound annual growth rate. In Colorado, Washington, and Oregon, where cannabis products for recreational use were legalized before 2016, consumers spending on cannabis were up 62% between 2015 and September 2016. ChineseInvestors.com, Inc. (OTC: CIIX), 22nd Century Group Inc. (NYSE: XXII), Medical Marijuana Inc. (OTC: MJNA), OWC Pharmaceuticals (OTC: OWCP), Through Terra Tech Corporation (O TC: TRTC)
As a result of the industry's growth, experts now expect a shift from sales on the black market, to gain steam in the legal cannabis market. "It's one of the major reasons that people are going to leave the underground market to go to the aboveground market. It's about variety," Arcview CEO Troy Dayton told Business Insider. "You just can't get these products on the underground market."
ChineseInvestors.com, Inc. (OTCQB: CIIX) on February 1st announced, the launch of its new website for its new subsidiary ChineseCBDoil.com. The website went live on January 31st, under the URL: http://www.ChineseCBD oil.com.
The Company is expanding into the medical marijuana industry with the launch of its website, and plans to retail hemp oil and related products, which are legal to sell and distribute within China, and in the United States, in all fifty states (hemp oil is not marijuana, but indeed a separate and distinct plant made from hemp). CBD oil, derived from hemp is a product with medicinal qualities that are primarily used for anti-inflammatory and other common ailments.
Mr. Warren Wang, the Chairman of ChineseInvestors.com stated: "I am very pleased to see the investor reaction to our announced plans which we began to disclose over a month ago. Indeed the market has responded with very strong interest in our shares, and as a result, we have achieved record trading volume and reached a new fifty-two week high in our shares last week."
Plant biotechnology company, 22nd Century Group Inc. (NYSE: XXII), is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants, through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties, development of X-22, a smoking cessation aid consisting of very low nicotine cigarettes, manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes, production of SPECTRUM research cigarettes for the National Institute on Drug Abuse; contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol, plants with high levels of cannabidiol, and other non-THC cannabinoids.
Development-stage company that operates in the cannabis and industrial hemp space in America, Medical Marijuana Inc. (OTCQB: MJNA), announced that its subsidiary HempMeds(R) Mexico, had held a press conference in Mexico, to reveal the positive results of a recent study conducted by renowned Mexican physician, Dr. Saul Garza Morales, on the effects of the Company's Real Scientific Hemp Oil-X(TM) (RSHO-X(TM)) prod uct in treating children with severe epilepsy. The study, conducted by Mexican pediatric neurologist Dr. Garza, included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X(TM) 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 7 reported a complete elimination of all seizures, over a 4-month period, with zero reported side effects.
OWC Pharmaceuticals (OTCQB: OWCP) is focused on the development of two delivery systems: A proprietary, cannabinoid-enriched sublingual tablet and a proprietary topical compound. The company developed its cannabinoid-enriched sublingual tablet for the admin istration of medical cannabis, near the end of last year. The tablet was developed to increase the bioavailability of cannabinoids and provide an optimal administration method for consistent dosing. The company plans to develop the tablet to treat conditions like multiple myeloma, post-traumatic stress disorder, and fibromyalgia. OWC Pharmaceuticals formulated a topical cannabinoid-based cream for the treatment of psoriasis, in partnership with Emilia Cosmetics Ltd., one of Israel's largest cosmetic manufacturers.
Through Terra Tech Corporation (OTCQX: TRTC) together with its subsidiaries, engages in the design, marketing, and sale of hydroponic equipment with proprietary technology, to create sustainable solutions for the cultivation of indoor agriculture in Newport Beach and Irvine, California . It operates through two segments: Hydroponic Produce and Cannabis Products. It also operates as a retail seller of hydroponic produce, herbs, and floral products, which are distributed in the Midwest and the Northeast United States; and produces and sells a line of cannabis flowers and cigarettes, as well as a line of cannabis pure concentrates, including oils, waxes, shatters, and clears to dispensaries in California.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report f rom NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Fina ncial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees f or producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com has been compensated three thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors. com inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their ow n independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All m aterials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information: Media Contact: E-mail: info@financialbuzz.com Phone: +1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201703175340&Transmission_Id=201703170900PR_NEWS_USPR_____enUK201703175340&DateId=20170317
I do not even have an acct at merrill lynch. this is someone close I know at Merrill.
From my Merrill Lynch guy (TIFWIW):
so yea a week late but there's a reason. Cat is about to be let out of the bag. And that cat is fat. you will see why this is soon to be a $10+ stock. No Brainer. Market will drool over this. Lot of reasons and more coming soon after.
BusinessWire, GlobeNewswire and PR Newswire News
OWC Pharmaceutical Research Corp OWCP:OTCQB
Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry
PR Newswire
8:30 AM ET
NetworkNewsWire Editorial Coverage
The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market's massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (NYSE:IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), OWC Pharmaceutical Research Corp. (OTC:OWCP), Insys Therapeutics, Inc. (NASDAQ:INSY) and GW Pharmaceuticals plc (NASDAQ:GWPH) are carving lanes of unprecedented opportunities in th e medical field.
Bethesda, Maryland-based India Globalization Capital (NYSE:IGC) (IGC Profile) is advancing the development of cannabis-based therapies targeting large market conditions and illnesses. IGC is on a mission to treat chronic and terminal neurological and oncological diagnoses and other life altering conditions utilizing an exciting and specialized IP platform that formulates and tests combination therapies. With this special focus in mind, IGC has amassed a portfolio of patent filings covering the indications of pain, medical refractory epilepsy and cachexia (cancer-induced anorexia) using cannabinoids. As we will further discuss later, IGC has established an approach that significantly differentiates the company from its cannabis-pharma peers.
Like IGC, Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to the development of innovative cannabinoid treatments that target seizures and pain. Unlike IGC and Cannabics, this clinical-stage, specialty pharmaceutical company is concentrating on developing transdermal synthetic cannabinoid treatments. On March 13, 2017, the company announced that it had completed enrolling patients for Phase 2 of its STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. Zynerba also revealed that it had completed enrollment for its Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.
OWC Pharmaceutical (OTCQB:OWCP), through its wholly owned One Word Cannabis Ltd. Israeli subsidiary, is focused on conducting medical research and pursuing clinical trials to develop cannabis-based pharmaceuticals and treatments for a variety of conditions. The company is developing two unique delivery systems to effectively dose and deliver medical cannabis. The first is a proprietary, cannabinoid-enriched sublingual tablet for the treatment of multiple myeloma, post-traumatic stress disorder, and fibromyalgia. In in-vitro testing, the tablets demonstrated 100% malignant cell death in 60% of infected mice cells. The second product is a proprietary topical compound for the treatment of psoriasis. In addition, OWC Pharmaceutical operates a Consulting Division created to help governments and companies nav igate complex international cannabis regulatory frameworks.
Another industry peer, Insys Therapeutics, Inc. (NASDAQ:INSY), is developing medications to treat addiction to opioids, opioid overdose, epilepsy and other disease areas with high unmet need. The commercial-stage company uses proprietary sublingual spray technology to develop pharmaceutical cannabinoids to address clinical shortcomings of products already on the market. Insys currently markets its FDA-approved SUBSYS(R) (fentanyl sublingual spray) for pain management in cancer patients who are tolerant to opioid therapy. The company has also received approval for Syndros(TM) for the treatment of chemotherapy-induced nausea and vomiting, as well anorexia associated with weight loss in persons with AIDS. Syndros is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC").
In terms of market share, the giant on the list of cannabis-focused biopharmaceutical companies is GW Pharmaceuticals (NASDAQ:GWPH), which is focused on the development of plant-derived cannabinoid therapeutics based on its proprietary cannabinoid product platform. The company's primary focus is on disorders of the central nervous system (CNS). Within this arena, GW's lead cannabinoid product candidate is Epidiolex(R) (cannabidiol), in development for the treatment of rare childhood-onset epilepsy disorders. The company's Sativex(R) (nabiximols) prescription drug, a therapy approved for the treatment of spasticity due to multiple sclerosis, is the world's first plant-derived cannabinoid prescription drug. Additionally, GW boasts a deep pipeline of additional cannabinoid product candidates which include clinical-stage compounds for glioma, schizophrenia and epilepsy.
It's an impressive and interesting lineup, but what sets India Globalization Capital (NYSE: IGC) (IGC Profile) apart from the other players is its foray into the larger market for cannabis-based combination therapies that would treat pain and other conditions. The company recently filed patents (http://nnw.fm/ggBB6) for formulations that will reduce the side effects of single drugs by being combined with a cannabinoid. IGC filed IGC-501 for a cannabis-based formulation to treat neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques.
India Globalization Capital also filed combination therapy formulations for the treatment of epilepsy/seizures (IGC-502) and cachexia (IGC-504). IGC-501, IGC-502 and IGC-503 are novel combination therapies that, if proven out by clinical trials, are expected to treat pain, medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional therapies.
Such 'combination therapies' have the unique opportunity to quickly move through the FDA's approval process, since the drugs have already been individually approved. Consequently, IGC believes it has 'first mover' advantage in pursuing this approach to bring cannabis-based pharmaceutical products to market in a quick and cost-effective manner.
The cannabis industry is growing in popularity. The wave of enthusiasm surrounding the recent legalization of cannabis in several new states is sweeping the country and IGC anticipates an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities and financial services. With a solid strategic plan in hand, this NYSE MKT listed company has a modest $9 million market capitalization which is just a fraction of their peer group, and is aggressively leaning on its connections to medical and procedural expertise to take advantage of one of many ground-floor opportunities. And, it is developing innovative therapies, while also acquiring technologies from related industries that will pl ace it in the right position for capitalizing on its first-mover advantage.
For more information on India Globalization Capital (IGC) please visit India Global Capital (IGC) or http://www.igcinc.us
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution compa ny with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is a source of content listed above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer or comparison to the profiled issuer. FN Media Group, LLC (FNM), is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker-dealer/analyst/adviser, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. NNW's compensation disclosure is incorporated herein and appears in ful l at http://NNW.fm/Disclaimer
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "sh ould", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW & FNM undertakes no obligation to update such statements.
Media Contact: FN Media Group, LLC editor@financialnewsmedia.com +1(954)345-0611
SOURCE NetworkNewsWire
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201703165224&Transmission_Id=201703160830PR_NEWS_USPR_____enUK201703165224&DateId=20170316
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
TD Ameritrade Logo
Securities Alert
Delivered by Markit On Demand
Account Log On
Sent: Thu Mar 16 2017 8:32:23 AM EDT
BusinessWire, GlobeNewswire and PR Newswire News
OWC Pharmaceutical Research Corp OWCP:OTCQB
Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry
PR Newswire
8:30 AM ET
NetworkNewsWire Editorial Coverage
The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market's massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (NYSE:IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), OWC Pharmaceutical Research Corp. (OTC:OWCP), Insys Therapeutics, Inc. (NASDAQ:INSY) and GW Pharmaceuticals plc (NASDAQ:GWPH) are carving lanes of unprecedented opportunities in th e medical field.
Bethesda, Maryland-based India Globalization Capital (NYSE:IGC) (IGC Profile) is advancing the development of cannabis-based therapies targeting large market conditions and illnesses. IGC is on a mission to treat chronic and terminal neurological and oncological diagnoses and other life altering conditions utilizing an exciting and specialized IP platform that formulates and tests combination therapies. With this special focus in mind, IGC has amassed a portfolio of patent filings covering the indications of pain, medical refractory epilepsy and cachexia (cancer-induced anorexia) using cannabinoids. As we will further discuss later, IGC has established an approach that significantly differentiates the company from its cannabis-pharma peers.
Like IGC, Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to the development of innovative cannabinoid treatments that target seizures and pain. Unlike IGC and Cannabics, this clinical-stage, specialty pharmaceutical company is concentrating on developing transdermal synthetic cannabinoid treatments. On March 13, 2017, the company announced that it had completed enrolling patients for Phase 2 of its STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. Zynerba also revealed that it had completed enrollment for its Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.
OWC Pharmaceutical (OTCQB:OWCP), through its wholly owned One Word Cannabis Ltd. Israeli subsidiary, is focused on conducting medical research and pursuing clinical trials to develop cannabis-based pharmaceuticals and treatments for a variety of conditions. The company is developing two unique delivery systems to effectively dose and deliver medical cannabis. The first is a proprietary, cannabinoid-enriched sublingual tablet for the treatment of multiple myeloma, post-traumatic stress disorder, and fibromyalgia. In in-vitro testing, the tablets demonstrated 100% malignant cell death in 60% of infected mice cells. The second product is a proprietary topical compound for the treatment of psoriasis. In addition, OWC Pharmaceutical operates a Consulting Division created to help governments and companies nav igate complex international cannabis regulatory frameworks.
Another industry peer, Insys Therapeutics, Inc. (NASDAQ:INSY), is developing medications to treat addiction to opioids, opioid overdose, epilepsy and other disease areas with high unmet need. The commercial-stage company uses proprietary sublingual spray technology to develop pharmaceutical cannabinoids to address clinical shortcomings of products already on the market. Insys currently markets its FDA-approved SUBSYS(R) (fentanyl sublingual spray) for pain management in cancer patients who are tolerant to opioid therapy. The company has also received approval for Syndros(TM) for the treatment of chemotherapy-induced nausea and vomiting, as well anorexia associated with weight loss in persons with AIDS. Syndros is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC").
In terms of market share, the giant on the list of cannabis-focused biopharmaceutical companies is GW Pharmaceuticals (NASDAQ:GWPH), which is focused on the development of plant-derived cannabinoid therapeutics based on its proprietary cannabinoid product platform. The company's primary focus is on disorders of the central nervous system (CNS). Within this arena, GW's lead cannabinoid product candidate is Epidiolex(R) (cannabidiol), in development for the treatment of rare childhood-onset epilepsy disorders. The company's Sativex(R) (nabiximols) prescription drug, a therapy approved for the treatment of spasticity due to multiple sclerosis, is the world's first plant-derived cannabinoid prescription drug. Additionally, GW boasts a deep pipeline of additional cannabinoid product candidates which include clinical-stage compounds for glioma, schizophrenia and epilepsy.
It's an impressive and interesting lineup, but what sets India Globalization Capital (NYSE: IGC) (IGC Profile) apart from the other players is its foray into the larger market for cannabis-based combination therapies that would treat pain and other conditions. The company recently filed patents (http://nnw.fm/ggBB6) for formulations that will reduce the side effects of single drugs by being combined with a cannabinoid. IGC filed IGC-501 for a cannabis-based formulation to treat neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques.
India Globalization Capital also filed combination therapy formulations for the treatment of epilepsy/seizures (IGC-502) and cachexia (IGC-504). IGC-501, IGC-502 and IGC-503 are novel combination therapies that, if proven out by clinical trials, are expected to treat pain, medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional therapies.
Such 'combination therapies' have the unique opportunity to quickly move through the FDA's approval process, since the drugs have already been individually approved. Consequently, IGC believes it has 'first mover' advantage in pursuing this approach to bring cannabis-based pharmaceutical products to market in a quick and cost-effective manner.
The cannabis industry is growing in popularity. The wave of enthusiasm surrounding the recent legalization of cannabis in several new states is sweeping the country and IGC anticipates an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities and financial services. With a solid strategic plan in hand, this NYSE MKT listed company has a modest $9 million market capitalization which is just a fraction of their peer group, and is aggressively leaning on its connections to medical and procedural expertise to take advantage of one of many ground-floor opportunities. And, it is developing innovative therapies, while also acquiring technologies from related industries that will pl ace it in the right position for capitalizing on its first-mover advantage.
For more information on India Globalization Capital (IGC) please visit India Global Capital (IGC) or http://www.igcinc.us
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution compa ny with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is a source of content listed above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer or comparison to the profiled issuer. FN Media Group, LLC (FNM), is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker-dealer/analyst/adviser, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. NNW's compensation disclosure is incorporated herein and appears in ful l at http://NNW.fm/Disclaimer
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "sh ould", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW & FNM undertakes no obligation to update such statements.
Media Contact: FN Media Group, LLC editor@financialnewsmedia.com +1(954)345-0611
SOURCE NetworkNewsWire
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201703165224&Transmission_Id=201703160830PR_NEWS_USPR_____enUK201703165224&DateId=20170316
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
All Good for us and for Medical MJ. Trump PRO Med MJ. And Sessions actually softened on REC Mj
LOL. Funny stuff
H UG E thx
again, you could not be more wrong. do your DD. Trump is PRO Med MJ. Best of luck